MENU
-
content validity：The CAR-T cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a tumor-specific antigen, then integrates the fragment into the transmembrane chain segment consisting of a series of molecules involved in T cell activation such as CD28, 4-1BB and CD3-ζ, forming a recombinant plasmid CAR. The CAR will be transduced into the T cells of a patient and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-T cells will be generated to attack and eventually ablate the tumor.
-
content validity：Chimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.
-
CAR-T Cell Therapycontent validity：The CAR-T cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a tumor-specific antigen, then integrates the fragment into the transmembrane chain segment consisting of a series of molecules involved in T cell activation such as CD28, 4-1BB and CD3-ζ, forming a recombinant plasmid CAR. The CAR will be transduced into the T cells of a patient and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-T cells will be generated to attack and eventually ablate the tumor.
-
CAR-NK Cell Therapycontent validity：Chimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.
